Establishing a dose-response relationship for haloperidol decanoate

Psychiatric Bulletin

Volumn 29, Issue 3, 2005, Pages 104-107

  Taylor, David ^a  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL DECANOATE; ZUCLOPENTHIXOL DECANOATE;

ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REGIMEN; HUMAN; META ANALYSIS; OPTIMAL DRUG DOSE; PLOTS AND CURVES; PUBLICATION; RECURRENCE RISK; SCHIZOPHRENIA;

EID: 14944358633     PISSN: 09556036     EISSN: None     Source Type: Journal    
DOI: 10.1192/pb.29.3.104     Document Type: Article

References (26)

1. ALTAMURA, A. O., TACCHINI, G. I., MAES, M. (1995) Haloperidol plasma 'threshold' levels for relapse prevention in schizophrenia: a study with haloperidol decanoate. European Neuropsychopharmacology Supplement, 55-58.
2. BECHELLI, L. P. C., IECCO, M. C., ACIOLI, A., et al (1985) A double-blind trial of haloperidol decanoate and pipothiazine palmitate in the maintenance treatment of schizophrenics in a public out-patient clinic. Current Therapeutic Research, 37, 662-671,
3. BRITISH MEDICAL ASSOCIATION AND THE ROYAL PHARMACEUTICAL SOCIETY OF GREAT BRITAIN (2003) British National Formulary. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain.
4. CHOUINARD, G., ANNABLE, L., CAMPBELL, W. (1989) A randomised clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. Journal of Clinical Psychopharmacology, 9, 247-253.
5. COOKSON, J. C., KENNEDY, N. M. & GRIBBON, D. (1986) Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double blind comparative trial of haloperidol decanoate and fluphenazine decanoate. International Clinical Psychopharmacology (suppl1), 41-51.
6. DAVIS, J. M., McKANE, J. M., MARDER, S. R., et al (1993) Dose reponse of prophylactic antipsychotics. Journal of Clinical Psychiatry, 54 (suppl), 24-30.
7. DAVIS, J. M., CHEN, N. & GLICK, I. D. (2003) A meta-analysis of the efficacy of second generation antipsychotics. Archives of General Psychiatry, 60, 553-564.
8. DENCKER, S. J., GIOS, I., MARTENSSON, E., et al (1994) A long term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients. Psychopharmacology, 114, 24-30.
9. EBERHARD, G. & HELLBORN, E. (1986) Haloperidol decanoate and flupenthixol decanoate in schizophrenia. Acta Psychiatrica Scandinavica, 74, 255-262.
10. EKLUND, K. & FORSMAN, A. (1991) Minimal effective dose and relapse - double blind trial: haloperidol decanoate vs. placebo. Clinical Neuropharmacology, 14, S7-S15.
11. GEDDES, J., FREEMANTLE, N., HARRISON, P., et al (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ, 321, 1371-1376.
12. HILTON, T., TAYLOR, D. & ABEL, K. (1996) Which dose of haloperidol? Psychiatric Bulletin, 20, 359-362.
13. KANE, J. M., DAVIS, J. M., SCHOOLER, N., et al (2002) A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. American Journal of Psychiatry, 159, 554-560.
14. KOSKINEN, T., WISTEDT, B. & THELANDER, S. (1991) Zuclopenthixol decanoate vs. haloperidol decanoate: A double blind comparative study. Biological Psychiatry, 1, 563-565.
15. McKANE, J. P., ROBINSON, A. D. T., WILES, D. H., et al (1987) Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenia in-patients. British Journal of Psychiatry, 151, 333-336.
16. MEYEROWITZ, W., JARAMILLO, J. D. C., DENSON, D., et al (1989) Optimum therapeutic dosing with haloperidol decanoate. Current Therapeutic Research, 46, 1174-1178.
17. QURAISHI, S. & DAVID, A. (2000) Depot haloperidol decanoate for schizophrenia (Cochrane Review). In: The Cochrane Library, issue 4. Chichester, UK: John Wiley & Sons, Ltd.
18. STONE, C. K., GARVER, D. L., GRIFFITH, J., et al (1995) Further evidence of a dose-response threshold for haloperidol in psychosis. American Journal of Psychiatry, 152, 1210-1212.
19. TAUSCHER, J. & KAPUR, S. (2001) Choosing the right dose of antipsychotics in schizophrenia. CNS Drugs, 15, 671-678.
20. TAYLOR, D. (1999) Depot antipsychotics revisited. Psychiatric Bulletin, 23, 551-553.
21. TAYLOR, D. (2000) Low dose typical antipsychotics - a brief evaluation. Psychiatric Bulletin, 24, 465-468.
22. VAN PUTTEN, T., MARDER, S. R. & MINTZ, J. (1990) A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Archives of General Psychiatry, 47, 754-758.
23. WISTEDT, B. (1984) A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients. International Clinical Psychopharmacology, 1 (suppl 1), 15-23.
24. WISTEDT, B., PETSSON, T. & HELLBORN, E. (1984) A clinical double-blind comparison between haloperidol decanoate and fluphenazine decanoate. Current Therapeutic Research, 35, 804-814.
25. WISTEDT, B., KOSKINEN, T., THELANDER, S., et al (1991) Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia; a double blind multicentre study. Acta Psychiatrica Scandinavica, 84, 14-16.
26. ZISSI, N. P., PSARAS, M. & KYKETSOS, G. (1982) Haloperidol decanoate, a new long-acting antipsychotic in chronic schizophrenia: a double blind comparison with placebo. Current Therapeutic Research, 31, 650-655.